You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, October 2020
|
| DOI | 10.1158/1535-7163.mct-20-0250 |
| Pubmed ID | |
| Authors |
Qiaqia Li, Kilia Y. Liu, Qipeng Liu, Guangyu Wang, Weihua Jiang, Qingshu Meng, Yang Yi, Yongyong Yang, Rui Wang, Sen Zhu, Chao Li, Longxiang Wu, Dongyu Zhao, Lin Yan, Lili Zhang, Jung-Sun Kim, Xiongbing Zu, Anthony J. Kozielski, Wei Qian, Jenny C. Chang, Akash Patnaik, Kaifu Chen, Qi Cao |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 22% |
| United Kingdom | 1 | 6% |
| Australia | 1 | 6% |
| Unknown | 12 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 72% |
| Scientists | 4 | 22% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 14% |
| Student > Bachelor | 2 | 10% |
| Student > Master | 2 | 10% |
| Other | 1 | 5% |
| Researcher | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 12 | 57% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 24% |
| Medicine and Dentistry | 1 | 5% |
| Unknown | 15 | 71% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2024.
All research outputs
#4,180,933
of 25,728,855 outputs
Outputs from Molecular Cancer Therapeutics
#799
of 4,088 outputs
Outputs of similar age
#97,450
of 434,786 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#11
of 53 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,088 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 434,786 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.